New hope for Hard-to-Treat sarcomas? early trial launches

NCT ID NCT07602777

Recruiting now Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 16, 2026 · Updated 3 times

Summary

This study tests a new medicine called Risvutatug Rezetecan (Ris-Rez) in adolescents and adults with advanced bone or soft tissue sarcomas that have come back or spread and can't be removed by surgery. The goal is to see if the drug can slow cancer growth and how safe it is. About 113 participants will receive Ris-Rez along with a supportive drug (G-CSF) to help manage side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Risvutatug Rezetecan (Ris-Rez), a biologic drug given by infusion, plus G-CSF to support white blood cell counts
What this could lead to: If it works, this could offer a new treatment option for people with advanced sarcomas that have stopped responding to other therapies.
What could go wrong: This is an early-phase trial with only 113 participants, so results may not apply to everyone. The drug may cause side effects or fail to control the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteosarcoma sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SARCOMA

Contacts and locations

Locations

GSK Investigational Site
RECRUITING

Toronto, Ontario, M5G 2M9, Canada
GSK Investigational Site
RECRUITING

Montreal, Quebec, QC H3H 2R9, Canada
GSK Investigational Site
RECRUITING

Bordeaux, 33076, France
GSK Investigational Site
RECRUITING

Lyon, 69373, France
GSK Investigational Site
RECRUITING

Villejuif, 94805, France
GSK Investigational Site
RECRUITING

Hokkaido, 003-0804, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.